Abstract
To evaluate the prognostic and molecular mechanisms of sex and racial differences in gastric cancer, data from two large centers were used to retrospectively analyze the survival of gastric cancer patients with regard to sex and racial differences. In examining the molecular mechanism of sex in gastric cancer patients of different races, data from The Cancer Genome Atlas database were used to analyze differentially expressed genes (DEGs), and Gene Ontology (GO) enrichment and DNA methylation analyses were performed. Among White gastric cancer patients, it was found that the survival prognosis for females was better than that for males; conversely, among Chinese patients, males had a better prognosis. For African Americans, sex may have an impact on gastric cancer, but this relationship was unclear. The expression of different core genes and differences in pathways are likely to be the main causes affecting the variation observed among gastric cancer patients of different races and sexes.
Introduction
Gastric cancer remains a significant global health challenge, consistently ranking as the third leading cause of cancer-related mortality. While it is well-established that the incidence of gastric cancer is approximately twice as high in men as in women, the influence of biological sex on survival outcomes has remained controversial and inconsistent across various studies.
A critical limitation in existing literature is the tendency to treat gastric cancer as a homogeneous disease, often overlooking how the intersection of sex and race influences clinical outcomes and molecular drivers. This study aims to bridge this gap by integrating large-scale clinical data with genomic and epigenetic analyses to identify race-specific prognostic factors and their underlying molecular mechanisms.
Methods
The study utilized a multi-center retrospective design, drawing from two primary clinical sources: the Surveillance, Epidemiology, and End Results (SEER) database (1973–2013) for White and Black patients in the U.S., and the Center for Gastric Cancer Research at Sun Yat-sen University (1994–2017) for Asian (Chinese) patients.
To ensure comparability between sexes, Propensity Score Matching (PSM) was applied to control for confounding variables such as age, tumor grade, and stage. Molecular analysis was conducted using mRNA expression and DNA methylation data from The Cancer Genome Atlas (TCGA), identifying Differentially Expressed Genes (DEGs) via the limma R package. Functional enrichment was performed using Gene Ontology (GO) analysis, and findings were validated using the KMPlot database.
Key Results
The analysis revealed a striking "prognostic reversal" between racial groups. In the White population, female sex was a significant protective factor for overall survival (OS). Conversely, in the Asian population, males exhibited superior survival outcomes. For Black patients, the relationship was more complex, with an initial female survival advantage in earlier cohorts that became statistically insignificant in more recent data.
Molecular Drivers by Race
The study identified distinct "core genes" driving these disparities:
- White Patients: Survival was influenced by genes related to RNA binding and transcription, including GYG2P1, RPS4Y1, TXLNG, and EIF1AX. High expression of GYG2P1 and RPS4Y1 correlated with poor prognosis.
- Black Patients: Molecular differences were centered on cellular structural changes, involving genes such as DNAJC5, HDAC10, NEO1, and SMG5.
- Asian Patients: Disparities were driven by cell surface receptor and G-protein coupled signaling pathways, with core genes including TMSB4Y, UTY, ZFY, and ZNF787.
Epigenetic analysis suggested that DNA hypomethylation is a primary mechanism for the upregulation of these core genes, physically altering genomic accessibility in a sex- and race-specific manner.
Discussion and Limitations
These findings highlight the necessity of considering both race and sex in the clinical management of gastric cancer. The identified core genes may serve as valuable biomarkers or therapeutic targets tailored to specific patient demographics.
However, the study has limitations. Its retrospective nature introduces potential selection bias. Furthermore, cancer staging standards evolved significantly over the 40-year study period. The broad categorization of "Asian" in the SEER database may also mask sub-ethnic differences. Finally, while the clinical cohorts were large, the TCGA molecular subsets for Black and Asian patients were relatively small, requiring further validation in larger genomic studies.
Summary updated